Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Amazon has reported for 6 months of 2023

8/4/23 AMZN

Moscow Exchange may launch short-term CFAs for cash claims

8/4/23 MOEX

Airbnb reported for 6 months of 2023

8/4/23 ABNB

SPB Exchange will admit 100 more Hong Kong-listed securities to trading by the end of the year

8/4/23 SPBE

Globaltruck reported for 6 months of 2023 by RAS

8/4/23 GTRK

X5 Retail Group takes measures to maintain its listing on the Moscow Exchange

8/3/23 -

Volume of transactions in the OTC equity market with CCs exceeded ₽10 billion

8/3/23 MOEX

Warner Bros. Discovery reported for 6 months 2023

8/3/23 WBD

Rostelecom reported for 6 months of 2023 by RAS

8/3/23 RTKM

Moderna reported for 6 months of 2023

8/3/23 MRNA